All In Biotech

Drug Trial Radar · NCT04784091

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Last checked: Nov 20, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Apr 29, 2021

Primary completion

May 9, 2022

Study completion May 9, 2022

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.

Conditions

  • Blepharitis

Interventions

  • TP-03Drug

    TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day

  • TP-03 VehicleDrug

    Vehicle of TP-03 ophthalmic solution, administered twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid.Time frame: 43 days

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Global Retina Institute

    Scottsdale, Arizona

  • Shultz Chang Vision

    Northridge, California

  • East Bay Eye Center

    San Ramon, California

  • Vision Institute

    Colorado Springs, Colorado

  • Pinnacle Research Institute

    Fort Lauderdale, Florida

  • Jackson Eye, S.C.

    Lake Villa, Illinois

  • Pankratz Eye Institute

    Columbus, Indiana

  • Michael Washburn Center for Ophthalmic Research LLC

    Indianapolis, Indiana

  • Kannarr Eye Care

    Pittsburg, Kansas

  • The Eye Care Institute

    Louisville, Kentucky

  • Complete Eye Care of Medina

    Medina, Minnesota

  • Tauber Eye Center

    Kansas City, Missouri

  • Ophthalmology Associates

    St Louis, Missouri

  • NC Eye Associates

    Apex, North Carolina

  • Pure Ophthalmic Research

    Mint Hill, North Carolina

  • Vita Eye Clinic

    Shelby, North Carolina

  • Northern Ophthalmic Associates

    Jenkintown, Pennsylvania

  • Alpine Research Organization / Healthy Heart Clinics of America

    Clinton, Utah

  • Alpine Research Organization Inc./ Country Hills Eye Center

    Ogden, Utah

  • Periman Eye Institute

    Seattle, Washington

  • New River Vision Care

    Oak Hill, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.